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Attenuation of Choroidal Thickness
in Patients With Alzheimer Disease
Evidence From an Italian Prospective Study
Alessandro Trebbastoni, MD, PhD,* Michela Marcelli, MD,w
Fabiana Mallone, MD,w Fabrizia D’Antonio, MD,* LetiziaAQ2 Imbriano,*
Alessandra Campanelli, MD,* Carlo de Lena, MD,*
and Magda Gharbiya, MDw
Introduction: To compare the 12-month choroidal thickness (CT)
change between Alzheimer disease (AD) patients and normal
subjects.
Methods: In this prospective, observational study, 39 patients with
a diagnosis of mild to moderate AD and 39 age-matched control
subjects were included. All the subjects underwent neuro-
psychological (Mini Mental State Examination, Alzheimer disease
Assessment Scale-Cognitive Subscale, and the Clinical Dementia
Rating Scale) and ophthalmological evaluation, including spectral
domain optical coherence tomography, at baseline and after 12
months. CT was measured manually using the caliper tool of the
optical coherence tomography device.
Results: After 12 months, AD patients had a greater reduction of
CT than controls (Pr0.05, adjusted for baseline CT, age, sex, axial
length, and smoking).
Discussion: CT in patients with AD showed a rate of thinning
greater than what could be expected during the natural course of
aging.
Key Words: Alzheimer disease, biomarker, choroidal thickness,
optical coherence tomography, enhanced depth imaging
(Alzheimer Dis Assoc Disord 2016;00:000–000)
Alzheimer disease (AD) is the most common cause ofdementia in the elderlies. Progressive extracellular
deposition of amyloid-b (Ab) protein and the accumulation
of fibrous material (neurofibrillary tangles) within some
neurons represent the neuropathologic hallmarks of the
disease.1 These main pathologic features coexist with a
number of structural and functional microvascular abnor-
malities identified in the brain of affected patients: cerebral
blood flow reduction; loss or abnormal cholinergic inner-
vation resulting in arterial hypercontractility and increased
vascular resistance; vascular anatomical defects such as
atrophy of arterioles and capillaries associated with
reduced microvascular density and extensive endothelial
degeneration; and cerebral amyloid angiopathy with Ab
deposits in the vascular smooth muscle cells of cerebral
arterioles and around cerebral capillaries.2–7 Altogether,
these cerebral vascular changes are believed to decrease Ab
peptide clearance across the blood-brain barrier and to lead
to oxidative stress and neurotoxicity that precede the onset
of clinical dementia.8–10
Increasing evidence suggests that ocular vasculature
may also be affected in AD and it has been speculated that
ocular vascular changes share similar pathogenic mecha-
nisms with that of cerebral vasculature. Retinal vascular
abnormalities, such as vessels attenuation and reduction of
retinal blood flow, have been described both in vivo, and in
transgenic animal models of AD.11–14
More recently, choroidal involvement was also
observed. In a previous study, our group, using high-
resolution spectral domain optical coherence tomography
(OCT), found a significant reduction of choroidal thickness
(CT) in AD patients.15 Bayan et al16 confirmed this novel
finding in a subsequent cross-sectional study on 31 AD
patients. The similar thinning of the choroid was further
demonstrated in a histopathologic study on a rat model of
AD and human postmortem retinal samples from AD
donors.17 The choroid naturally thins with aging, with an
estimated 1.56 mm decrease in thickness for each year of
age.18 Our working hypothesis is that CT in patients with
AD may show a rate of thinning greater than what could be
expected during the natural course of aging. Parallel with
cerebral vascular impairment, choroidal thinning may
represent a novel biomarker of disease severity and
progression.
In this exploratory study we compared CT change
over a period of 12 months between patients with AD and
normal subjects.
METHODS
Study Subjects
This was a prospective, observational study on
patients with a diagnosis of mild-to-moderate AD who
were consecutively recruited at the outpatient clinic of the
Department of Neurology and Psychiatry of the Umberto I
University Hospital (Rome, Italy), from May 2012 to May
2014. Informed consent was obtained from all subjects
involved in the study and the Local Ethics Committee
approved the experimental protocol. The research followed
the tenets of the Declaration of Helsinki.
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The diagnosis of probable AD was made according to
the National Institute of Neurologic and Communicative
Disorders and Stroke-Alzheimer disease and Related Dis-
orders Association (NINCDS-ADRDA) criteria.19 The
findings in some of these patients have previously been
published in a precedent article.15 Cognitively healthy, age-
matched volunteers were enrolled, as controls, among the
unaffected companions of patients attending the out-
patients’ service of the Eye Clinic of the Umberto I Uni-
versity Hospital. Patients and controls underwent physical
and neurological assessment, standard laboratory tests,
serum vitamin B12, folate and thyroid hormone assays. A
complete neuropsychological evaluation including the Mini
Mental State Examination (MMSE), the Alzheimer disease
Assessment Scale-Cognitive Subscale/11 items (ADAS-
Cog), and the Clinical Dementia Rating Scale (CDR) was
performed during the enrollment phase and was repeated at
12 months. Patients were included if they met the following
criteria: age between 55 and 85 years; MMSE score between
19 and 26; CDR score between 1 and 2; a Modified
Hachinski Ischemic Scaler4; have a magnetic resonance
imaging scan showing cortical atrophy involving the medial
temporal lobes and the hippocampus20; and have a Fazekas
scales less than grade 2.21 Patients’ exclusion criteria were:
secondary dementia (ie, vitamin deficiency or severe hypo-
thyroidism, hydrocephalus, syphilis, alcohol abuse);
degenerative dementia other than AD; or vascular dementia
diagnosed according to the National Institute of Neuro-
logical Disorders and Stroke and Association Inter-
nationale pour la Recherch´e et l’Enseignement en Neuro-
sciences (NINDS-AIREN) criteria.22 Control subjects’
cognitive inclusion criteria were: MMSE>26, ADAS-
Cog<20, and CDR=0. Patients and controls were
excluded if they had: severe carotid artery stenosis;
uncontrolled hypertension; diabetes mellitus; history of
repeated head trauma or protracted loss of consciousness
following head trauma within the last 5 years; severe central
nervous system infections within the last 5 years; and his-
tory of cerebrovascular disease (ie, stroke, transient ische-
mic attacks, cerebral hemorrhage). We also excluded sub-
jects suffering from psychiatric comorbidities or receiving
antidepressant, antipsychotic or antiepileptic drugs. Anti-
cholinesterase inhibitors were, instead, allowed.
Eye Examination
Patients and controls underwent a complete oph-
thalmologic evaluation, including best-corrected visual
acuity (BCVA) measurements using the Early Treatment
Diabetic Retinopathy Study chart at 4m, ocular biometry
(IOL Master, Carl Zeiss Meditec, Dublin, CA), anterior
segment biomicroscopy, intraocular pressure with Gold-
mann tonometry, dilated fundus examination, fundus pho-
tography, and OCT.
Ocular exclusion criteria were: BCVA <20/25;
refractive error> ±3 spherical equivalent; axial length
<22 and >26mm; intraocular pressure>18mm Hg, cup/
disc ratio>0.5; optic disc anomaly such as, tilted disc or
peripapillary atrophy; pre-existing macular pathologies
such as age-related macular degeneration (AMD), epi-
retinal membrane or macular hole; other retinopathies such
as retinal vascular occlusion or retinal dystrophy; pre-
existing ocular diseases such as glaucoma or uveitis; history
of any neuro-ophthalmologic disease; amblyopia; previous
intraocular surgery or laser treatment except for cataract
surgery performed at least 12 months before enrollment;
any intraocular surgery during the study period; use of
topical medication or systemic therapy with known inter-
ference on retinal thickness such as steroids and diuretics;
and low quality (<20 units) OCT images.
In the included participants, the ophthalmologic
evaluation, including BCVA measurement and OCT, was
repeated after 12 months from baseline assessment as well
as the neuropsychological assessment.
OCT
Patients and controls underwent OCT examination
using the Heidelberg Spectralis (Spectralis Family Acquis-
ition Module, Version 5.1.6.0; Heidelberg Engineering,
Heidelberg, Germany) with Heidelberg Eye Explorer (Ver-
sion 1.7.1.0), following a standardized protocol described
elsewhere.15 All scans were acquired in high-resolution
mode by an experienced operator who was masked to the
subject’ diagnosis. Active eye tracking (TruTrack) and
automatic follow-up scan (AutoRescan) were used to enable
1
3
5
7
9
11
13
15
17
19
21
23
25
27
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85
87
89
91
93
95
97
99
101
103
105
107
109
111
113
115
117
119
121
123
125
127
129
TABLE 1. Alzheimer Disease Patients Versus Controls:
Demographics and Baseline Clinical Characteristics
AD Patients Controls P
Age (y) 71.1±7.2 70.8±6.7 0.8*
Sex (M/F) 18/21 17/22 1.0w
Memory symptoms
duration (range, min
to max) (y)
2.9±1.7
1-7
Axial length (mm) 23.5±0.7 23.4±0.6 0.5*
ACD (mm) 3.2±0.5 3.2±0.4 0.9*
Corneal curvature (mm) 7.8±0.2 7.7±0.3 0.9z
Spherical equivalent
(Diopters)
+0.6±0.7 +0.5±0.8 0.6z
Phakic/pseudophakic 23/16 25/14 0.8w
Intraocular pressure
(mm Hg)
13.8±1.7 13.6±1.4 0.6z
BCVA (no. ETDRS
letters)
54±3.8 57±4.1 F=7.4
0.009y
Scholar (range, min to
max) (y)
9.0±3.8
2-17
9.3±4.7
5-17
0.8z
MMSE score (range,
min to max)
22.5±2.1
19-26
28.6±1.4
27-30
<0.0001z
ADAS-Cog (range, min
to max)
31.1±5.9
20-43
9.2±3.5
3-19
<0.0001z
CDR (range, min to
max)
1.4±0.2
1-2
0.0±0.0
0
<0.0001z
Glycaemia (mg/dL) 80.9±6.7 81.6±7.1 0.7*
LDL AQ4-cholesterol (mg/
dL)
82.5±11.4 81.3±12.2 0.7*
Total-cholesterol (mg/
dL)
197.3±13.2 198.7±13.0 0.6*
Systolic blood pressure
(mm Hg)
132.7±6.5 131.8±7.0 0.6z
Diastolic blood pressure
(mm Hg)
74.7±5.2 74.2±5.9 0.7z
Smoking/no smoking 11/28 9/30 0.8w
Values are mean±SD unless otherwise indicated.
*Unpaired t test with Levene test for equality of variances.
wFisher exact test.
zMann-Whitney U test
yDifferences in BCVA between groups were determined by the general
linear model including age, sex, and axial length as covariates.
ACD indicates anterior chamber depth; AD, Alzheimer disease; ADAS-
Cog, Alzheimer Disease Assessment Scale; BCVA, best-corrected visual
acuity; CDR, Clinical Dementia Rating Scale; ETDRS, Early Treatment
Diabetic Retinopathy Study; MMSE, Mini Mental State Examination.
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point-to-point correspondence between consecutive follow-
up scans.
The spectral domain OCT images of the choroid were
acquired by enhanced depth imaging modality. Two high
quality, 30 degrees horizontal and vertical line scans
through the fovea with 60 to 100 frames averaged for each
scan were obtained. CT was measured using the manual
caliper tool provided with the software of the OCT device.
CT from the horizontal and vertical line scans was meas-
ured by 2 of the coauthors that were masked to the subjects’
diagnosis, and values were averaged. These measurements
were made of the subfoveal choroid and at 500 and 1500 mm
from the center of the fovea.
Statistical Analysis
In prestudy sample size calculations, whichAQ3 were based
on data from a previous study carried out in normal eyes,[36]
enrollment of 38 eyes per group, would provide 80.0% power
to detect as little as a 20% difference in the CT between cases
and controls (assuming 2-sided tests and a=0.05). Sample
size calculation was carried out with the commercial software
IBM SPSS Sample Power for Windows (SPSS Inc., Chicago,
IL). Statistical analysis was performed with the SPSS for
windows (Version 17.0, SPSS). One eye from each participant
was randomly chosen to perform the analysis. Normal
distribution of data was analyzed by the Kolmogorov-
Smirnov test. Parametric variables were compared using the
unpaired t test. Levene test was used to verify variance
homogeneity. Nonparametric distributed values were ana-
lyzed by the Mann-Whitney rank sum test. Categorical var-
iables were compared using the Fisher exact test. Longi-
tudinal data were analyzed using the paired t test or the
Wilcoxon test, as appropriate. OCT measurements’ changes
from baseline between groups were compared using the
general linear model, including the baseline OCT measure-
ment, age, sex, axial length, and smoking as covariates.
Bivariate relationships were evaluated by the Spearman
coefficient or the Pearson analysis, as appropriate. Interob-
server repeatability for CT measurements was tested with the
intraclass test/retest correlation. Data are reported as mean
values±SD. P-values of <0.05 were considered as statisti-
cally significant.
RESULTS
Baseline Evaluation
Altogether, 65 patients with AD were consecutively
evaluated. Twenty patients were excluded at time of
enrollment: 8 were affected with AMD, 5 had an epiretinal
membrane, 3 were affected with glaucoma, 2 had high
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TABLE 2. Alzheimer Disease Patients Versus Controls: Baseline Choroidal Thickness Measurements
AD Patients Controls Coefficient, P ICC (95% CI)*
Subfoveal CT (mm) 194.0±70.8 284.3±75.6 F=8.1, 0.007w 0.98 (0.97-0.99)
Superior CT 500 (mm)z 202.1±74.8 277.9±83.2 F=6.8, 0.01w 0.97 (0.96-0.98)
Superior CT 1500 (mm)z 210.8±76.1 282.3±81.8 F=6.8, 0.01w 0.97 (0.96-0.98)
Inferior CT 500 (mm)z 186.8±76.0 268.5±82.9 F=8.8, 0.005w 0.96 (0.95-0.97)
Inferior CT 1500 (mm)z 177.0±74.8 270.9±83.2 F=10.9, 0.002w 0.97 (0.96-0.98)
Temporal CT 500 (mm)z 200.4±68.7 270.6±71.4 F=6.2, 0.02w 0.97 (0.96-0.98)
Temporal CT 1500 (mm)z 194.9±56.8 252.2±60.0 F=5.8, 0.02w 0.96 (0.94-0.98)
Nasal CT 500 (mm)z 183.3±79.3 267.8±80.3 F=8.1, 0.007w 0.97 (0.95-0.98)
Nasal CT 1500 (mm)z 141.5±67.5 204.8±78.6 F=5.8, 0.02w 0.96 (0.94-0.97)
Values are mean±SD unless otherwise indicated.
*Interexaminer correlation coefficients for choroidal thickness measurements at baseline.
wDifferences in measurements between groups were determined by the general linear model including age, sex, axial length, and smoking as covariates.
zDenotes the position 500 mm superior to the fovea. The same naming convention is used for the subsequent entries.
AD indicates Alzheimer disease; CI, confidence interval; CT, choroidal thickness; ICC, intraclass test/retest correlation.
TABLE 3. Alzheimer Disease Patients Versus Controls: Changes in Best-corrected Visual Acuity and Psychometric Scores Over 12 months
AD Patients Controls
T0 T12 P T0 T12 P P
BCVA (no. ETDRS letters) 54±3.8 53±3.5 0.01* 57±4.1 57±4.2 0.7*
BCVA change 1.3±2.3 0.4±2.1 F=9.6, 0.004w
MMSE 22.5±2.1 16.8±2.8 <0.0001z 28.6±1.4 28.3±1.2 0.5z
MMSE change 5.7±4.0 0.1±1.1 <0.0001y
ADAS-Cog 31.1±5.9 38.7±5.4 <0.0001z 9.2±3.5 9.6±3.1 0.3z
ADAS-Cog change 7.6±4.3 0.4±1.3 <0.0001y
CDR 1.4±0.2 1.9±0.3 <0.0001z 0.0±0.0 0.0±0.0 —
CDR change 0.5±0.4 0.0±0.0 <0.0001y
Values are mean±SD unless otherwise indicated.
*Paired t test.
wDifferences in BCVA change from baseline between groups were determined by the general linear model including baseline BCVA, age, sex, and axial
length as covariates.
zWilcoxon test.
yMann-Whitney U test.
AD indicates Alzheimer disease; ADAS-Cog, Alzheimer Disease Assessment Scale; BCVA, best-corrected visual acuity; CDR, Clinical Dementia Rating
Scale; ETDRS, Early Treatment Diabetic Retinopathy Study; MMSE, Mini mental State Examination.
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myopia, and 2 patients were excluded because of low
quality OCT. Six patients dropped out during the 12-month
follow-up period: 3 patients cited personal reasons and 3
underwent cataract surgery in both eyes. Thirty-nine eyes of
39 patients (mean age, 71.1±7.2 y; range, 58 to 80 y; 21
women) with a diagnosis of mild to moderate AD and 39
eyes of 39 age-matched control subjects (mean age,
70.8±6.7 y; range, 60 to 82 y; 22 women) were finally
included in this 1-year prospective study. The demographic
and clinical characteristics of patients at baseline are shown
in Table 1. In AD patients, the Fazekas scores for peri-
ventricular and white matter hyperintensities were
0.70±0.5 (range, 0 to 1) and 0.6±0.5 (range, 0 to 1),
respectively. Compared with controls, baseline BCVA was
worse in AD patients (F=7.4, P=0.009). As expected,
psychometric parameters (MMSE, ADAS-Cog, CDR) were
all significantly worse in patients (P<0.0001) compared
with control subjects. At baseline, CT at each location was
significantly reduced in AD compared with controls
(P<0.05, adjusted for age, sex, axial length, and smoking)
(Table 2).
Month 12 Evaluation
After 12 months, the cognitive functions, as assessed by
MMSE, ADAS-Cog 11, and CDR, were generally declined in
patients (P<0.0001) while remained unaffected in healthy
subjects. Psychometric scores changes were all significantly
different between groups (P<0.0001). Compared with
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FIGURE 1. RepresentativeAQ5 images of choroidal thickness measurements as assessed with spectral domain optical coherence tomography
in a patient with Alzheimer disease at baseline (A) and at month 12 (B). The patient’s psychometric scores were: MMSE=25, ADAS-
Cog=37, and CDR=0.5, at baseline and MMSE=20, ADAS-Cog=41, and CDR=1.5, at 12 months. Choroidal thickness measurements
in a healthy subject at baseline (C) and at month 12 (D). Results of psychometric test were: MMSE=29, ADAS-Cog=8, and CDR=0, at
baseline and MMSE=30, ADAS-Cog=8, and CDR=0, at 12 months. ADAS-Cog indicates Alzheimer disease Assessment Scale-Cognitive
Subscale; CDR, Clinical Dementia Rating Scale; MMSE, Mini Mental State Examination.
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baseline, BCVA significantly decreased in patients (P=0.01),
while remained unchanged in controls. The BCVA decrease
was significantly more prominent in AD patients compared
with controls (F=9.6, P=0.004), (Table 3). Compared with
baseline, CT at each location decreased significantly after 12
months in the AD group (P<0.001) whereas no significant
reduction was observed in controls (Fig. 1). The decrease in
CT was significantly more prominent in patients compared
with controls (Pr0.05, adjusted for baseline CT, age, sex,
axial length, and smoking), (Table 4). No correlations were
found between psychometric scores’ changes and neither
baseline CT nor CT changes.
DISCUSSION
Our results at 12 months showed a significant CT
reduction in AD patients. Compared with healthy subjects,
choroidal thinning was significantly more prominent in AD.
It is noteworthy, that there is an age-related reduction in CT
of about 1.6mm for each year of age.18 Herein, at 12
months, AD patients showed a mean decrease in subfoveal
CT of about 10mm, which is greater than what could be
expected during the natural course of aging. This evidence
suggests that the rate of choroidal thinning over time might
represent a potential disease-specific event in AD, not linked
to the physiological choroidal involution due to senescence.
In a precedent cross-sectional study, comparing CT
between AD patients and healthy subjects, we demon-
strated a significant reduction of CT in AD.15 We postu-
lated that choroidal thinning observed in AD might be
related to a series of pathologic events triggered by local Ab
deposition similar to what can be found in the cerebral
vascular system in AD.
Age-dependent Ab accumulation in the choroidal vas-
culature has been demonstrated both in normal aging mouse
and in a transgenic mouse model of AD.23,24 More recently,
Tsay AQ6et al demonstrated Ab plaques accumulation in the
choroid as well as choroidal thinning in a novel transgenic rat
model of AD.17 In addition, the authors observed the
recruitment of microglia and the activation of complement
protein C suggesting an inflammatory response in the cho-
roidal vascular system. As in the brain, Ab accumulation in the
choroid might induce inflammatory response and complement
activation that progressively lead to neurodegeneration and
vasoregression of the choroidal vasculature through the same
pathologic cascade already described in AD brains.4,25,26
Hence, the changes of CT we found in our patients could
resemble, in vivo, the progression of the disease within the eye.
Despite that, no significant correlation emerged between cho-
roidal thinning and the psychometric scores. However, this
could depend on the small size of the sample enrolled.
As highlighted in our previous article, the hypothesis
that the reduction of CT in AD could depend on Ab-medi-
ated toxicity directly within the choroid is also in line with the
evidences of similar mechanisms of choroidal damage in
AMD, where Ab accumulation has also been described.27
Park et al28 demonstrated that Ab42 was expressed in the
retinal pigment epithelium layer of a mouse model of AD,
which showed characteristic features of dry AMD. Of note,
among the different phenotypes of AMD, the dry subtype is
the one predominantly associated with choroidal thinning
and atrophy. Further, it has recently been observed that
patients with dry AMD are also at greater risk of cognitive
impairment.29 Hence, choroidal thinning found in our
patients, similar to that described in AMD, further supports
the hypothesis that a common pathogenic mechanism might
exist between the 2 degenerative pathologies.
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TABLE 4. Alzheimer Disease Patients Versus Controls: Measurements’ Changes of Choroidal Thickness Over 12 months
AD Patients Controls
T0 T12 P T0 T12 P Coefficient, P ICC (95% CI)*
Subfoveal CT (mm) 194.0±70.8 183.3±72.2 0.0001w 284.3±75.6 282.4±75.3 0.1w 0.98 (0.97-0.99)
Change 10.7±11.4 2.0±9.7 F=9.4, 0.004z
Superior CT 500 (mm)y 202.1±74.8 190.5±74.2 0.0002w 277.9±83.2 275.5±80.2 0.3w 0.97 (0.95-0.98)
Change 11.6±11.9 2.6±10.8 F=4.4, 0.04z
Superior CT 1500 (mm)y 210.8±76.1 196.3±72.1 <0.0001w 282.3±81.8 279.2±81.3 0.1w 0.98 (0.97-0.99)
Change 14.6±14.4 3.1±10.0 F=5.2, 0.03z
Inferior CT 500 (mm)y 186.8±76.0 174.2±75.2 <0.0001w 268.5±82.9 266.3±80.4 0.1w 0.97 (0.95-0.98)
Change 12.2±11.5 2.2±10.7 F=6.0, 0.02z
Inferior CT 1500 (mm)y 177.0±74.8 164.8±77.4 0.0005w 270.9±83.2 266.7±80.6 0.3w 0.96 (0.94-0.98)
Change 12.2±16.4 4.1±11.4 F=4.6, 0.04z
Temporal CT 500 (mm)y 200.4±68.7 189.7±65.9 <0.0001w 270.6±71.4 267.4±72.6 0.2w 0.96 (0.94-0.98)
Change 10.8±8.7 3.2±7.1 F=8.6, 0.005z
Temporal CT 1500 (mm)y 194.9±56.8 183.4±55.2 0.0003w 252.2±60.0 248.7±59.1 0.1w 0.96 (0.94-0.98)
Change 11.5±13.1 3.5±8.9 F=7.4, 0.01z
Nasal CT 500 (mm)y 183.3±79.3 172.8±77.5 <0.0001w 267.8±80.3 265.5±79.5 0.3w 0.97 (0.95-0.98)
Change 10.5±8.6 2.3±7.9 F=6.3 0.02z
Nasal CT 1500 (mm)y 141.5±67.5 128.9±62.7 <0.0001w 204.8±78.6 202.4±79.1 0.4w 0.97 (0.96-0.98)
Change 12.6±12.0 2.4±9.0 F=11.4, 0.002z
Values are mean±SD unless otherwise indicated.
*Interexaminer correlation coefficients for choroidal thickness measurements at 12 months.
wPaired t test.
zDifferences in measurements change from baseline between groups were determined by the general linear model including baseline choroidal thickness,
age, sex, axial length, and smoking as covariates.
yDenotes the position 500 mm superior to the fovea. The same naming convention is used for the subsequent entries.
AD indicates Alzheimer disease; CI, confidence interval; CT, choroidal thickness; ICC, intraclass test/retest correlation.
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Our finding that AD patients had significantly poorer
visual acuity when compared with their normal counterpart
should be emphasized. Accordingly, compared with con-
trols, AD patients showed a significant visual acuity wor-
sening over time. Our results are consistent with those of a
recently published study by Nolan et al.30 The visual dys-
function in AD has previously been thought to be only
attributed to damage in the primary visual cortex and
higher cortical areas. However, increasing evidence shows
that precortical degeneration also plays a role.31–33 Given
its important role in maintaining retinal pigment epithelium
and outer retina, the choroid is considered to be important
for visual acuity.34 Indeed, a direct correlation between CT
and visual acuity has recently been shown in major ocular
pathologies such as myopia and AMD.35–37
The main limitations of the present study are the small
sample size and that choroidal analysis was based on
nonautomated measurements on 2 single-line OCT scans.
Further, as we did not use cerebrospinal fluid biomarkers
or scans with Ab PET ligands, some issues on diagnostic
accuracy in our sample could arise. The strengths of this
work include the prospective, longitudinal design, and the
high rate of adherence to a strict protocol.
In conclusion, our study demonstrated that, compared
with healthy subjects, AD patients showed a significant
greater reduction of CT over a period of 12 months.
However, future studies using the state-of-the-art instru-
ments (ie, swept source OCT) are necessary to confirm our
observations. Further appropriate prospective comparative
studies of larger patient populations are also needed to
establish the diagnostic and prognostic role of OCT anal-
ysis compared with the other dynamic research biomarkers
available in AD.
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